- Home
- MLKN vs INBX Comparison
MLKN vs INBX Comparison
Compare MLKN & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLKN | INBX |
|---|---|---|
| Founded | 1905 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | 1994 | 2024 |
Fundamental Metrics
Financial Performance| Metric | MLKN | INBX |
|---|---|---|
| Price | $15.45 | $102.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | ★ 625.8K | 489.3K |
| Earning Date | 03-25-2026 | 05-15-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $3,669,900,000.00 | $1,300,000.00 |
| Revenue This Year | $5.94 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | 1.14 | ★ 550.00 |
| 52 Week Low | $13.77 | $12.80 |
| 52 Week High | $23.18 | $155.29 |
Technical Indicators
Market Signals| Indicator | MLKN | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 45.50 |
| Support Level | $15.36 | $99.20 |
| Resistance Level | $16.34 | $153.14 |
| Average True Range (ATR) | 0.57 | 13.75 |
| MACD | 0.02 | -3.93 |
| Stochastic Oscillator | 57.63 | 8.06 |
Price Performance
Historical ComparisonAbout MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract, International Contract, and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.